Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03516981
Title A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-small cell carcinoma

Therapies

MK-1308 + Pembrolizumab

MK-4280 + Pembrolizumab

Lenvatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | CAN

Additional content available in CKB BOOST